Establishment and characterization of a novel patient-derived cell line from conventional central grade 3 chondrosarcoma, NCC-CS1-C1.

IF 3.4 3区 生物学 Q3 CELL BIOLOGY Human Cell Pub Date : 2024-12-08 DOI:10.1007/s13577-024-01152-0
Rei Noguchi, Takuya Ono, Julia Osaki, Yuki Adachi, Shuhei Iwata, Yomogi Shiota, Kazuyoshi Yanagihara, Shogo Nishino, Takaya Funada, Koichi Ogura, Akihiko Yoshida, Akira Kawai, Tadashi Kondo
{"title":"Establishment and characterization of a novel patient-derived cell line from conventional central grade 3 chondrosarcoma, NCC-CS1-C1.","authors":"Rei Noguchi, Takuya Ono, Julia Osaki, Yuki Adachi, Shuhei Iwata, Yomogi Shiota, Kazuyoshi Yanagihara, Shogo Nishino, Takaya Funada, Koichi Ogura, Akihiko Yoshida, Akira Kawai, Tadashi Kondo","doi":"10.1007/s13577-024-01152-0","DOIUrl":null,"url":null,"abstract":"<p><p>Chondrosarcoma (CS) is a malignant tumor that produces cartilaginous matrix and is the second most common primary bone sarcoma. CS encompasses a range of histological subtypes, with high-grade conventional central CS being particularly rare, occurring at a rate of 1.81 cases per 1 million person-years. Complete surgical resection is the standard curative treatment for this subtype, as radiation therapy and chemotherapy have proven ineffective. High-grade conventional central CS is highly metastatic and prone to recurrence, resulting in a poor prognosis. Therefore, effective multidisciplinary treatment strategies are urgently needed. Patient-derived cell lines offer promising tools for exploring new therapeutic approaches. However, only two cell lines of high-grade CSs are currently available in public cell banks. In this study, we aimed to establish a novel cell line for high-grade conventional central CS. We successfully developed the NCC-CS1-C1 cell line using surgically resected tumor tissues from a patient with conventional central grade 3 CS. This cell line harbored an IDH1 mutation (p.R132S), commonly found in 50% of CS cases, and exhibited complex copy number variants. A high-throughput screening of 221 anti-cancer drugs identified five candidates-bortezomib, carfilzomib, doxorubicin, panobinostat, and romidepsin-that demonstrated low IC50 values, indicating potential efficacy in treating CS. These findings suggest that NCC-CS1-C1 is a valuable tool for both preclinical and basic research on high-grade conventional central CS.</p>","PeriodicalId":49194,"journal":{"name":"Human Cell","volume":"38 1","pages":"28"},"PeriodicalIF":3.4000,"publicationDate":"2024-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Cell","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1007/s13577-024-01152-0","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Chondrosarcoma (CS) is a malignant tumor that produces cartilaginous matrix and is the second most common primary bone sarcoma. CS encompasses a range of histological subtypes, with high-grade conventional central CS being particularly rare, occurring at a rate of 1.81 cases per 1 million person-years. Complete surgical resection is the standard curative treatment for this subtype, as radiation therapy and chemotherapy have proven ineffective. High-grade conventional central CS is highly metastatic and prone to recurrence, resulting in a poor prognosis. Therefore, effective multidisciplinary treatment strategies are urgently needed. Patient-derived cell lines offer promising tools for exploring new therapeutic approaches. However, only two cell lines of high-grade CSs are currently available in public cell banks. In this study, we aimed to establish a novel cell line for high-grade conventional central CS. We successfully developed the NCC-CS1-C1 cell line using surgically resected tumor tissues from a patient with conventional central grade 3 CS. This cell line harbored an IDH1 mutation (p.R132S), commonly found in 50% of CS cases, and exhibited complex copy number variants. A high-throughput screening of 221 anti-cancer drugs identified five candidates-bortezomib, carfilzomib, doxorubicin, panobinostat, and romidepsin-that demonstrated low IC50 values, indicating potential efficacy in treating CS. These findings suggest that NCC-CS1-C1 is a valuable tool for both preclinical and basic research on high-grade conventional central CS.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
一种来自常规3级中枢软骨肉瘤NCC-CS1-C1的新型患者来源细胞系的建立和表征
软骨肉瘤(CS)是一种产生软骨基质的恶性肿瘤,是第二常见的原发性骨肉瘤。CS包括一系列组织学亚型,高级别常规中枢性CS特别罕见,发生率为每100万人年1.81例。由于放疗和化疗已被证明无效,完全手术切除是该亚型的标准治疗方法。常规中枢性高级别CS转移性高,易复发,预后差。因此,迫切需要有效的多学科治疗策略。患者来源的细胞系为探索新的治疗方法提供了有希望的工具。然而,目前在公共细胞库中只有两种高级CSs细胞系可用。在这项研究中,我们旨在建立一种新的高级常规中央CS细胞系。我们利用手术切除的肿瘤组织成功地开发了nc - cs1 - c1细胞系,该肿瘤组织来自传统的中心3级CS患者。该细胞系携带IDH1突变(p.R132S),通常在50%的CS病例中发现,并表现出复杂的拷贝数变异。221种抗癌药物的高通量筛选确定了5种候选药物——硼替佐米、卡非佐米、阿霉素、帕比司他和罗米地辛,这些药物的IC50值较低,表明治疗CS有潜在疗效。这些发现表明,NCC-CS1-C1是高级别常规中枢CS临床前和基础研究的宝贵工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Human Cell
Human Cell CELL BIOLOGY-
CiteScore
5.90
自引率
2.30%
发文量
176
审稿时长
4.5 months
期刊介绍: Human Cell is the official English-language journal of the Japan Human Cell Society. The journal serves as a forum for international research on all aspects of the human cell, encompassing not only cell biology but also pathology, cytology, and oncology, including clinical oncology. Embryonic stem cells derived from animals, regenerative medicine using animal cells, and experimental animal models with implications for human diseases are covered as well. Submissions in any of the following categories will be considered: Research Articles, Cell Lines, Rapid Communications, Reviews, and Letters to the Editor. A brief clinical case report focusing on cellular responses to pathological insults in human studies may also be submitted as a Letter to the Editor in a concise and short format. Not only basic scientists but also gynecologists, oncologists, and other clinical scientists are welcome to submit work expressing new ideas or research using human cells.
期刊最新文献
Nimodipine ameliorates subarachnoid hemorrhage-induced neuroinflammation and injury by protecting mitochondrial function and regulating autophagy. The multifaceted roles of aldolase A in cancer: glycolysis, cytoskeleton, translation and beyond. Inhibitory effects of the combination of rapamycin with gemcitabine plus paclitaxel on the growth of pancreatic cancer tumors. High glucose induces renal tubular epithelial cell senescence by inhibiting autophagic flux. The dual role of PTPN22 in immune modulation and transplantation tolerance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1